Skip to main content Skip to main navigation menu Skip to site footer

Correlation Between Serum Calcium and Parathyroid Hormone in Chronic Kidney Disease Patients

  • Wahyudi Pratama Harli ,
  • Hasyim Kasyim ,
  • Pendrik Tandean ,
  • Syakib Bakri ,
  • Nur Ahmad Tabri ,
  • Arifin Seweng ,

Abstract

Introduction:  Chronic kidney disease (CKD) is commonly associated with secondary hyperparathyroidism. Elevated phosphorus concentrations and decreased synthesis of active vitamin D (calcitriol) as a direct result of impaired renal function induce a cascade of symptoms, including decreased calcium absorption and increased parathyroid hormone (PTH) secretion. This study aimed to assess the association between calcium levels and PTH levels in patients diagnosed with CKD.

Methods:   A cross-sectional observational study was conducted involving a cohort of 80 individuals diagnosed with CKD who met the established criteria. The statistical tests employed in this study were Pearson's correlation. Statistically significant findings are obtained from these tests when the p-value is below 0.05.

Results: This study demonstrates a correlation between decreased levels of calcium in the blood and increased levels of PTH in persons with impaired kidney function.   In eighty patients with CKD stages 3 to 5, regardless of dialysis status, a clear inverse correlation (-0.328, P = 0.000) was observed between parathyroid hormone and serum calcium levels.

Conclusion: Patients with CKD showed a significant inverse correlation between their blood serum calcium levels and PTH levels.   Hence, it is imperative to assess the concentrations of blood calcium and PTH in individuals with CKD and a glomerular filtration rate below 60 ml/min/1.73 m2.

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
  2. Karim AMA, Kasim H, Albaar A, et al. The correlation between serum fibroblast growth factor-23 levels and left ventricular hypertrophy in chronic kidney disease patients. J Ren Inj Prev. Published online December 4, 2023. doi:10.34172/jrip.2023.32227
  3. Siswanto H, Mallapasi M, Mulawardi M, et al. The Effect of Heparin Lock and Topical Antibiotics on Catheter- Related Bloodstream Infection Events in Chronic Kidney Disease with Short-Term Double-Lumen Catheter Patients. Surg Gastroenterol Oncol. Published online June 30, 2022. doi:10.21614/sgo-eC-429
  4. Waziri B, Duarte R, Naicker S. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-276. doi:10.2147/IJNRD.S191156
  5. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Włodarczyk Z, Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23(1):115-126. doi:10.1081/jdi-100001291
  6. Habas ES, Eledrisi M, Khan F, Elzouki A-NY. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. 2021;13(7):e16388. doi:10.7759/cureus.16388
  7. Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. Blood Purif. 2009;27(4):338-344. doi:10.1159/000209246
  8. Tejwani V, Qian Q. Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients. 2013;5(6):1913-1936. doi:10.3390/nu5061913
  9. Cannata-Andía JB, Carrera F. The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. NDT Plus. 2008;1(Suppl 1):i2-i6. doi:10.1093/ndtplus/sfm037
  10. Carneiro Dias RS, José de Araújo Brito D, Milhomem Dos Santos E, et al. Correlation Between Parathyroid Hormone Levels with Urinary Magnesium Excretion in Patients with Non-Dialysis Dependent Chronic Kidney Disease. Int J Nephrol Renovasc Dis. 2020;13:341-348. doi:10.2147/IJNRD.S282106
  11. Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Debakey Cardiovasc J. 2017;13(2):49-54. doi:10.14797/mdcj-13-2-49
  12. Bellorin-Font E, Voinescu A, Martin KJ. Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder. In: Kopple JD, Massry SG, Kalantar-Zadeh K, Fouque DBT-NM of RD (Fourth E, eds. Nutritional Management of Renal Disease. Fourth. Academic Press; 2022:353-381. doi:https://doi.org/10.1016/B978-0-12-818540-7.00013-6
  13. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737-747. doi:10.1038/ki.2012.176
  14. Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D. The role of phosphate in kidney disease. Nat Rev Nephrol. 2017;13(1):27-38. doi:10.1038/nrneph.2016.164
  15. Moe SM. Rationale to reduce calcium intake in adult patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(4):251-257. doi:10.1097/MNH.0000000000000416
  16. Gallieni M, Cucciniello E, D’Amaro E, et al. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol. 2002;15(2):165-170. http://www.ncbi.nlm.nih.gov/pubmed/12018633
  17. Sah DK, Haque SS, Shah S, Yadav SS. Role of Calcium, Phosphorus and Intact Parathyroid Hormone in Different Stages of Chronic Kidney Disease. J Clin Exp Nephrol. 2023;8(2):185. doi:10.36648/2472-5056.8.2.185
  18. Arora K, Goyal G, Soin D, Kumar S, Arora H, Garg C. Correlation of Parathyroid Hormone Levels with Mineral Status in End-stage Renal Disease Patients. Indian J Endocrinol Metab. 2018;22(6):735-739. doi:10.4103/ijem.IJEM_279_18
  19. Ennis J, Worcester E, Coe F. Contribution of calcium, phosphorus and 25-hydroxyvitamin D to the excessive severity of secondary hyperparathyroidism in African-Americans with CKD. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012;27(7):2847-2853. doi:10.1093/ndt/gfs080
  20. Rastogi A, Kumar S, Kumar R, Singh AK, Kumar C, Prakash G. Cross-sectional Study of Calcium Phosphate Product and Intact Parathyroid Hormone Levels in Predialysis and Postdialysis Patients with Stage 5 Chronic Kidney Disease. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2021;32(4):967-972. doi:10.4103/1319-2442.338308
  21. Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients? Med Princ Pract Int J Kuwait Univ Heal Sci Cent. 2011;20(1):85-89. doi:10.1159/000319768
  22. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2011;26(6):1938-1947. doi:10.1093/ndt/gfq304
  23. Jean G, Mayor B, Hurot J-M, et al. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(1):176-182. doi:10.1093/ndt/gfs119

How to Cite

Harli, W. P., Hasyim Kasyim, Pendrik Tandean, Syakib Bakri, Nur Ahmad Tabri, & Arifin Seweng. (2024). Correlation Between Serum Calcium and Parathyroid Hormone in Chronic Kidney Disease Patients. Bali Medical Journal, 13(1), 662–667. https://doi.org/10.15562/bmj.v13i1.5106

HTML
18

Total
5

Share

Search Panel